Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-02-13
Schrodinger, Inc.
Schrödinger develops computational chemistry software for molecular discovery and also runs collaboration and internal drug discovery programs that can generate milestone and royalty economics.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Physics-plus-AI software re-rate hinges on packaging
The 5-year upside is driven by shifting value capture from licensed tools to a metered, auditable discovery runtime embedded in automated workflows. Execution risk centers on enterprise scale-up timing, burn discipline, and avoiding commoditization via trust and governance features.

Analysis

Thesis
As AI makes “molecular cognition” cheaper, SDGR can win by becoming the audited execution layer for discovery (API-first, compliance logs, validated physics+AI), shifting monetization from seats to metered campaigns/enterprise controls and using collaborations/partnering to fund upside without runaway dilution.
Last Economy Alignment
Direct beneficiary of cheaper compute + automation in R&D; strongest leverage is trusted, workflow-embedded prediction + auditability (not attention). Main drag is buyer power/in-sourcing risk if tools commoditize.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.4x (from 5 most recent analyses)
Reasoning
SDGR’s non-linear upside is a packaging and distribution story more than a new-science story: make the Python API the primary commercial surface, meter high-throughput discovery runs, and sell governance (provenance/audit logs/version pinning) as the premium feature that procurement can’t easily replace with “free” tools. The Jan-2026 platform integrations (e.g., LiveDesign integrations) plus Predictive Toxicology expansion broaden wallet share, while partnering clinical assets can reduce burn and keep the equity story software-led. If executed, SDGR can re-rate from a mixed model with burn concerns toward a durable life-science software/tools multiple.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risk is distribution friction: renewals and large-account expansions can be delayed by procurement and platform standardization decisions. Strategically, SDGR must prevent software value capture from drifting toward commoditized tooling by selling trust (auditability, validated accuracy, reproducibility) and embedding into automated workflows via the API. Financially, sustained operating burn makes partnering (or deprioritizing) clinical assets important to avoid dilution during periods when software growth is merely steady, not accelerating.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$24.33
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case